Clinical trials: CAR NK
Leukemia, Hematopoetic Stem Cell Transplantation
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a…
- Conditions
- Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy
- Trial name
- Allo-X (NCT06643221)
- Testing
- Exercise, Isoproterenol, Bisoprolol Fumarate Tablet 10 mg
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Acute Lymphocytic Leukemia in Relapse
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
Immunotherapy has shown promise in treating hematological malignancies, including resistant B-ALL. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer…
- Trial name
- NCT06631040
- Testing
- anti CD19 CAR NK cells
- Where
- Iran
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific…
- Trial name
- NCT06242249
- Testing
- Anti-BCMA CAR-NK
- Where
- Iran
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Healthy Donors, Myeloproliferative Diseases
CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors
Recent studies demonstrated the safety and efficacy of allogeneic and autologous infusion of NK cells as adoptive immunotherapy in malignant hematological diseases and solid tumors.NK cells are innate immunity effectors with…
- Conditions
- Healthy Donors, Myeloproliferative Diseases, Lymphoproliferative Disorders
- Trial name
- NCT06727383
- Testing
- peripheral blood collection, leukapheresis
- Where
- Italy
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology